belite

Belite Bio Announces UKs Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

November 02, 2025 09:00 ET  | Source: Belite Bio, Inc MHRA response is based on the Phase 3 DRAGON interim…

3 weeks ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

July 02, 2025 03:00 ET  | Source: Belite Bio, Inc -  500 subjects enrolled across the United States, the United…

5 months ago